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Alzheimer’s disease is a common and devastating disease for which there is no readily available biomarker to aid
diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has
used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral
tissue. We performed a case–control study of plasma using this proteomics approach to identify proteins that
differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with
Alzheimer’s dementia were recruited through secondary services and 50 normal elderly controls through
primary care. For validation purposes a total of 511 subjects with Alzheimer’s disease and other neurodegen-
erative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the
gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the
changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in
the disease pathology, including complement factor H (CFH) precursor and a-2-macroglobulin (a-2M). Using
semi-quantitative immunoblotting, the elevation of CFH and a-2M was shown to be specific for Alzheimer’s
disease and to correlate with disease severity although alternative assays would be necessary to improve
sensitivity and specificity. These findings suggest that bloodmay be a rich source for biomarkers of Alzheimer’s
disease and that CFH, together with other proteins such as a-2M may be a specific markers of this illness.
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Abbreviations: AMD ¼ age-related macular degeneration; a-2M ¼ a-2-macroglobulin; CFH ¼ complement factor H;
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Background
Alzheimer’s disease is the most common dementing illness
of late life, affecting >20% of those aged over 80 years.
Diagnosis is made primarily on clinical grounds and, to date,
there is no reliable diagnostic test. With the emergence of
disease modification therapies there is an increasing need
for diagnostic markers to ensure that therapies are targeted
at the correct patient population, to initiate early treatment
and to monitor disease course.
Several studies have investigated biochemical biomarkers
for this disease in various tissues including blood (Zhang
et al., 2004) and CSF (Hampel et al., 2004). Of these
approaches, the most reproduced findings are of decreased
Ab42 and increased total tau and phospho-tau in CSF in
Alzheimer’s disease relative to normal ageing and non-
dementia late life neuropsychiatric conditions (Blennow and
Hampel, 2003; Sunderland et al., 2005). However, lumbar
puncture is a relatively invasive procedure and obtaining
CSF, especially repeatedly, on large numbers of elderly
infirm individuals in the community is challenging. Blood,
on the other hand, is easy to obtain and as 500 ml of CSF
are absorbed into the blood every day, plasma may offer a
rich source of disease biomarkers. Furthermore damage to
the blood–brain barrier, a known event in this disease, may
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enhance movement of proteins between brain and blood,
in either direction (Zipser et al., 2006). We have therefore
sought to identify diagnostic biomarkers in peripheral
venous blood using proteomics. Samples from patients
and elderly controls were profiled by two-dimensional
gel electrophoresis (2-DGE) and proteins identified by
mass spectrometry and further validated by immunoblot
in Alzheimer’s disease and in other neurodegenerative
disorders relative to controls.
Material and methods
Subjects and samples
The main study population was derived from a largely community
based population of subjects with Alzheimer’s disease and elderly
people [Alzheimer’s Research Trust (ART) cohort]. Community or
nursing home resident cases with NINCDS-ADRDA probable
Alzheimer’s disease were identified from secondary care services
for elderly people with dementia. In addition to a clinical diagnosis,
subjects were assessed with a standardized assessment protocol
including informant interview for diagnosis and the MMSE
and Global Dementia Scale assessments for severity. Controls
with an MMSE score of >26 were recruited though primary care
age-sex registers or as spouses of cases. Samples were collected and
prepared as described in Supplementary Material. Subjects with
other neurodegenerative diseases were recruited through clinics at
King’s College Hospital and The Institute of Neurology, London.
Samples were collected and stored as described in Supplementary
Material, but in brief all samples were collected into EDTA coated
glass tubes and stored for up to 2 years at 80C. Samples from
normal controls, disease controls and cases were stored under
similar conditions.
Proteomics
Non-depleted plasma samples were analysed by isoelectric focusing
in the first dimension on immobilized pH (3–10) gradient strips
followed by PAGE in the second dimension. We chose, in this
study, not to deplete the samples of abundant proteins because
of concerns regarding non-specificity of all available depletion
methods (see Discussion). Gels were silver stained and analysed
quantitatively using the Melanie 2-D software version 3 to identify
spots that were identifiable in both case and control groups. Spots
that were significantly different between case and control groups
were excised and analysed by liquid chromatography tandem
mass spectrometry (LC/MS/MS). For validation plasma was
analysed by western blot with complement factor H (CFH) or
a-2-macroglobulin (a-2M) primary antibodies. Full details of all
methods are in Supplementary Material.
Statistics
Statistical analysis was performed using SPSS (v11), Genespring
(Silicon Genetics, Redwood City, CA), and STATA (v8) packages.
The mean integrated optical densities of spots on 2D gels in the
initial test and replication sets were analysed using Student’s
t-test. In the full sample integrated optical densities were tested
for normality using the Shapiro–Wilk test. Spots that we examined
were not normally distributed and so we therefore used non-
parametric tests (Mann–Whitney) combined with false discovery
rate (FDR) analysis as correction for multiple comparison testing.
Using the FDR as a criterion for further study by mass spectrometry
allowed us to avoid making a priori decisions about the significance
(in terms of fold change) of spots between cases and controls. For
correlation analyses individual protein integrated optical density
data were first scaled to unit variance so as to standardize the scales
upon which the variables were compared (i.e. each value was
divided by the standard deviation of all the values for that
particular variable). We then calculated the Pearson correlation
coefficient. Cases with missing values were excluded pairwise. Other
statistical tests are described in the text.
Results
Subject characteristics
In the core proteomics sample set of 100 subjects, cases
with Alzheimer’s disease were an average of 6.8 years older
than control subjects and were more likely to carry one or
two APOE «4 alleles (Table 1). For validation purposes
three independent sets of subjects were used – from the
ART cohort 266 subjects (146 controls, 111 with Alzheimer’s
disease, 9 with vascular dementia), from the KCL motor
neuron disease (MND) study cohort 175 subjects (43
controls, 100 with MND, 18 with multiple system atrophy
and 14 with other neurodegenerative, non-dementia diseases
including 9 with progressive supranuclear palsy), and from
the Institute of Neurology Huntington’s disease study 70
subjects (15 controls, 15 pre-symptomatic mutation carriers,
15 with mild Huntington’s disease and 25 with moderate or
severe Huntington’s disease). The study was approved by the
relevant research ethics committees.
2-DGE of human plasma proteins
To examine the profile of plasma proteins we compared
25 cases and 25 normal elderly control samples by 2-DGE.
We identified 217 protein spots that could be successfully
identified on silver staining and matched in cases and
controls (Fig. 1). We compared the mean integrated optical
density (a compound measure of intensity and size) of each
spot and found 15 that were significantly different between
cases and controls (P < 0.05; t-test variances not assumed
equal). We then repeated the experiment with a separate set
of 25 cases and 25 controls. In this set 27 spots showed
significant (P < 0.05) case–control differences and of these
five showed overlap—that is they were significantly different
between Alzheimer’s disease and controls in both the
original test set and in the replication set.




Mean age (SD) 73.6 (5.4) 80.4 (5.8)
% Female 78 80
% APOE «4/* 39.6 80
% APOE «4/4 0 12
Mean MMSE score (SD) 29.0 (1.03) 8.5 (7.4)
Mean GDS score (SD) 5.5 (1.03)
Mean duration of disease (years; SD) 7.9 (4.3)
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Class prediction using 2-DGE analysis
As there was reproducibility in the individual spot differ-
ences between cases and controls we then performed a
class prediction analysis in order to determine whether the
pattern of peptide spots on 2-DGE could predict clinical
caseness. We used Support Vector Machines (SVMs), a
supervised machine learning algorithm for prediction of
class set in a group based upon a training set of data (Aliferis
et al., 2002). SVM has previously been used as a class
prediction model for proteomic studies (Yang and Chou,
2004). Using GeneSpring (Silicon Genetics) we designated
the original 25 cases and 25 controls as a training set and
then the replication 25 cases and 25 controls as a test set. All
identified proteins were used as possible predictors and with
parameters polynomial dot product order 1 and diagonal
scaling factor 1 we correctly identified 34 of the 50 test-
samples as being either cases or controls. Sensitivity was
56% and specificity 80% using SVM analysis of 2-DGE data
alone.
Identification of proteins that differentiate
between cases and controls
We then compared spot density in both the initial set of
cases and controls and the replication set. We assessed mean
differences between patients and controls at each spot using
non-parametric tests. The P-values for the null hypothesis of
no mean differences were saved, sorted by increasing value
and ranked. A FDR index was computed and fifteen spots
were identified to have a FDR of <0.50. The proteins in these
fifteen spots were then identified using LC/MS/MS (Table 2).
Correlation of peptide spots with clinical
parameters
The cases differed from controls by being slightly older and
being more likely to carry an APOE «4 allele. It was possible
that the protein differences between cases and controls could
have been due to an association with these variables.
We therefore performed a correlation analysis for the 15
differing spots in all subjects by age and compared spot
density by APOE «4 status and gender. There were no
significant differences in any spot with gender but four spots
correlated with age and six spots were different in APOE «4
carriers (Table 3). As APOE genotype is itself highly
correlated with Alzheimer’s disease it was possible that case–
control differences were entirely or largely due to protein
differences in different APOE genotypes. We therefore
compared spot density in cases versus controls in APOE «4
carriers only. In one case (171) the case–control difference
Fig. 1 Plasma protein separation. Representative two-dimensional gel electrophoresis blot of plasma. The spots showing significant
differences between cases and controls (see Table 2) are labelled.
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was lost suggesting that this spot is a marker of APOE
rather than disease status. However with all other spots the
case–control difference was preserved. One spot showed
a weak correlation with MMSE (spot number 4; Pearson
correlation 0.3, P = 0.04).
Confirmation
In order to confirm the proteomic data we analysed by
western blotting the two spots containing proteins other
than albumin or immunoglobulins that showed the greatest
fold change between cases and controls—spot 2 containing
CFH and spot 4 containing a-2M. For CFH validation we
used three entirely separate sets of subjects from those used
in the 2-DGE experiments; one (ART) cohort recruited as
part of a study of Alzheimer’s disease but also including
some patients with vascular dementia (none of these subjects
overlapped with the 100 subjects used in the initial
proteomics study), one cohort recruited as part of a study
of MND but including some with MSA and some with PSP
and other non-dementia neurodegenerative disorders, and a
third cohort recruited as part of a study of Huntington’s
disease and including groups pre-symptomatic for the
disease and those with mild or moderate/severe disease. See
subject characteristics mentioned earlier.
We subjected equal volumes of plasma to immunoblot
for CFH protein and subsequent quantitative densitometry
(Fig. 2A). There was a highly significant difference across the
nine groups [controls, Alzheimer’s disease, VaD, MND,
MSA, PSP and related disorders (miscellaneous in Fig. 3),
pre-symptomatic Huntington’s disease, mild Huntington’s
disease, moderate/advanced Huntington’s disease; ANOVA,
Table 2 Proteins identified in plasma from Alzheimer’s disease and age-matched controls
Spot No. Rank P-value Fold change State change Protein ID Accession no.
196 1 0.0003 1.78 " AD Desmoplakin P15924
Ig kappa chain C region P01834
Ig kappa chain V-II region TEW P01617
Serum amyloid P-component precursor (SAP) P02743
171 2 0.0013 2.11 " AD Ig kappa chain C region P01834
Serum albumin precursor P02768
Galectin-7 P47929
2 3 0.0014 13.75 " AD Complement factor H (CFH) precursor P08603
Serum albumin precursor P02768
a-2-macroglobulin (a-2M) precursor P01023
Ceruloplasmin precursor P00450
184 4 0.0054 2.43 " AD Ig lambda chain C regions P01842
Ig lambda chain V-III region LOI P80748
Serum albumin precursor P02768
CFH related protein 2 precursor P36980
177 5 0.0054 1.92 " AD Ig lambda chain C regions P01842
Serum albumin precursor P02768
Ig lambda chain V-III region LOI P80748
Ig kappa chain C region P01834
4 6 0.0060 8.83 " AD a2-macroglobulin (a-2M ) precursor P01023
170 7 0.0117 1.98 " AD Ig lambda chain C regions P01842
Ig kappa chain C region P01834
Serum albumin precursor P02768
Ig lambda chain V-II region TRO P01707
Ig kappa chain V-I region Lay P01605
Ig kappa chain V-IV region Len P01625
13 8 0.0155 4.23 # AD Inter-alpha-trypsin inhibitor heavy chain H4 precursor Q14624
Ceruloplasmin precursor P00450
165 9 0.0183 1.58 # AD Serum albumin precursor P02768
164 10 0.0206 2.03 # AD Complement C4 precursor P01028
Ig gamma-1 chain C region P01857
14 11 0.0250 10.82 # AD Serum albumin precursor P02768
Histone H2B.a/g/h/k/l P62807
126 12 0.0290 1.6 # AD CD5 antigen-like precursor O43866
Serum albumin precursor P02768
Ig mu chain C region P01871
176 13 0.0291 1.75 " AD Ig lambda chain C regions P01842
Serum albumin precursor P02768
Ig lambda chain V-III region LOI P80748
123 14 0.0314 1.36 " AD Serum albumin precursor P02768
1 15 0.0347 3.32 " AD a-2M precursor P01023
Ig alpha-1 chain C region P01876
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F = 2.89, P < 0.005]. On post hoc testing the only difference
relative to controls was the 44.7% increase in Alzheimer’s
disease (Tukey’s; P < 0.01; 95% CI 0.83–0.07; Fig. 3). In the
Alzheimer’s disease set there was a modest but significant
correlation of CFH with MMSE (Pearson correlation
coefficient 0.2, P < 0.05) and a gradual (although not
significant; ANOVA) increase in CFH values with global
measures of severity.
We then determined a-2M levels in the dementia cohort
(in total both CFH and a-2M was successfully determined in
256 subjects; Alzheimer’s disease n = 111; controls n = 146;
Fig. 2B). There was a small but highly significant increase
in a-2M (0.99 versus 1.14; P < 0.001) but no significant
correlation with MMSE.
Finally we performed an ROC analysis for both proteins.
The area under the curve was very highly significant for both
(P < 0.005) but neither CFH nor a-2M showed favourable
test characteristics (Fig. 4). Setting specificity at 80% gave
a sensitivity value of 40% for CFH and 39% for a-2M.
The protein levels at these cut-offs (CFH 1.27; a-2M 1.18)
were then used for a combined analysis. Combining the
two proteins gave a sensitivity of 62%, specificity of 60%,
a positive predictive value 54% and a negative predictive
value of 68%.
Discussion
The study of human plasma proteome has become possible
as highly sensitive mass spectrometry technologies have
developed. Plasma is easy to obtain and contains many,
only partially characterized, proteins. The amount of these
proteins, or their modification, potentially reflects physio-
logical state in normal and/or diseased conditions and
may therefore be significant diagnostic markers, prognostic
markers or markers of disease progression. It remains
an open question whether such plasma biomarkers will be
Table 3 Spots showing significant differences by age or by
APOE status
Spot number Age APOE «4/*
Pearson P Difference t P
2 0.054 2.78 0.007
13 0.023 0.02
126 0.270 0.007 0.13 2.97 0.004
164 0.098 2.82 0.006
165 0.206 0.04
170 0.13 3.17 0.002
171 0.205 0.04
176 0.086 2.53 0.013
196 0.03 2.84 0.006
Fig. 4 Validation of change in key plasma proteins in Alzheimer’s
disease. ROC characteristics of a-2M and CFH. The area under the
curve was highly significant (CFH 0.64, P < 0.005; a-2M 0.61;
P < 0.001) but neither protein has the characteristics using this
assay of a biomarker (sensitivity and specificity >80%).
Fig. 2 Immunoblots of complement factor H and
a-2-macroglobulin. The spots from 2-DGE showing most sig-
nificant difference between cases and controls, identified by mass
spectrometry, as CFH and a-2M and these were validated by
western blotting. Representative blots are shown.
Fig. 3 Validation of change in CFH in Alzheimer’s disease. Plasma
from three cohorts was examined using western blotting with an
antibody to CFH. Samples from disease groups were compared
with control samples collected in the same studies. Significant
differences between the groups were due to the elevation of CFH
in the Alzheimer’s disease group (ANOVA post hoc Alzheimer’s
disease-control 0.45; 95% CI 0.83–0.07; P < 0.01). Error bars SEM.
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found for Alzheimer’s disease—most studies have searched
for such markers in CSF, as it is more likely to reflect the
metabolic state of brain (Sunderland et al., 2005). However,
plasma markers might exist if either plasma characteristics
change in response to brain disease or if Alzheimer’s disease
has a systemic metabolic state that is reflected in the
periphery. Both have previously been suggested (Mattila and
Frey, 1995). Various candidate proteins have previously been
examined in plasma and serum but no previous study has
used 2-DGE based proteomic methods in a large sample set.
One of the obstacles to performing any proteomic study
on plasma is the abundance of proteins such as albumin
and immunoglobulins (IgG). Various strategies have been
developed to deplete plasma of these proteins (Tam et al.,
2004) but there are at least three problems to all currently
available depletion strategies and some of these are inherent
to any depletion approach. First, and most problematical for
any depletion of proteins, is that the high abundant targets
of depletion may themselves be possible biomarkers. This is
exemplified in the results of this study where some proteins
shown to differ between cases and controls, including a-2M
and albumin itself, are primary targets of depletion. Indeed,
one of the most promising and specific depletion techniques
specifically targets a protein, a1-antichymotrypsin, pre-
viously shown to be a potential biomarker (DeKosky et al.,
2003; Zolotarjova et al., 2005). Secondly, commonly used
depletion strategies employed are relatively non-specific
and also remove very many non-target proteins including
for example CFH, one of the proteins we demonstrate to be
different between cases of Alzheimer’s disease, controls and
other neurodegenerative diseases (Szafranski et al., 2004;
Zolotarjova et al., 2005). Thirdly, even the most highly
specific depletion strategies deplete proteins other than their
primary targets and some of these could be potential
biomarkers (Yocum et al., 2005; Zolotarjova et al., 2005).
Thus for example the highly specific multiple affinity
removal column (Szafranski et al., 2004), although more
specific than dye-based systems, also removes transthyretin
which in Alzheimer’s disease is altered in CSF (Biroccio et al.,
2006) and apolipoprotein-A1 which is altered in plasma (Liu
et al., 2006). We concluded therefore that it is unlikely that
any existing method will turn out to be the definitive
approach to blood-based biomarker discovery and in this
study used a non-depletion strategy, recognizing that we
would ‘miss’ differences in proteins of the same molecular
weight as the main albumin and immunoglobulin bands.
Indeed some of the proteins, including a-2M and com-
plement C4 for example, that we show to be altered in
Alzheimer’s disease are depleted even by the most specific
depletion strategies available (Szafranski et al., 2004). In
fact it is probable that both depletion and non-depletion
strategies will each yield potential biomarkers, but whichever
approach is used in the discovery phase the critical step is
confirmation using another method. We have shown here,
that we can identify proteins that differ in plasma, without
depletion, between subjects with Alzheimer’s disease and
controls and have both replicated and confirmed these
changes in a large sample.
Using 2-DGE we detected >200 spots, each containing
multiple proteins that were successfully matched between
cases and controls. Of these, four protein spot differences
were replicated in a second test set of cases and controls.
Moreover, using a class prediction algorithm we were able to
identify cases from controls based on 2-DGE image analysis
alone, with a sensitivity of 56% and a specificity of 80%.
These data demonstrate that there are reproducible protein
differences in plasma between people with Alzheimer’s
disease and healthy and cognitively intact elderly controls.
2-DGE is a separation method that is most suitable for
relatively high molecular weight and relatively abundant
proteins and there are other approaches to investigating the
proteome some of which have been successfully applied to
biomarker discovery in neurodegeneration (Irizarry, 2004;
Lopez et al., 2005). It is likely that these methods are
complementary to those we used and that discovery of all
potential biomarkers will require a suite of approaches. Our
findings indicate that 2-DGE is a suitable method to
discover reproducible changes in plasma between cases and
controls.
In order to identify the proteins differentiating
Alzheimer’s disease from elderly controls we aggregated
the test and replication sample set data and then used non-
parametric analysis combined with FDR to identify all
those spots significantly different between cases and
controls. Using LC/MS/MS we have identified the peptide
constituents of all 15 protein spots with a FDR <0.5.
Interestingly, of these, some proteins have been previously
reported to show significant associations with this disease.
Of the 15 spots, 13 contained some component of
immunoglubulin or serum albumin precursor, nine showing
an increase and four a decrease in Alzheimer’s disease.
Previously, albumin and immunoglobulins have been
examined in CSF and in serum/plasma as a marker of
blood–brain barrier integrity with variable findings—some
showing a relative increase of immunoglubulins and/or
albumin in CSF but others not replicating this finding
(Hampel et al., 1995, 1999). In Down’s syndrome with
dementia, IgA and some classes of IgG but not IgM are
elevated (Mehta et al., 1993). More recently attention has
turned to specific immunological response in Alzheimer’s
disease with observed elevation of autoantibodies to the Ab
peptide (Nath et al., 2003). These findings have led to the
suggestion that this is an autoimmune disease (D’Andrea,
2005).
Some of the proteins we have identified have previously
been implicated in the pathology of this illness. The role of
a-2-macroglobulin (a-2M) has been of considerable interest
since it was shown that this proteinase inhibitor was present
in amyloid plaques (Bauer et al., 1991). This protein also
has a role in regulating immune response (Armstrong and
Quigley, 2001) being induced by inflammatory cytokines
(Strauss et al., 1992) and may be a marker of damage to
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the blood–brain barrier (Cucullo et al., 2003). Genetic
variation in both a-2M and its receptor LRP have been linked
with Alzheimer’s disease, although these associations have not
been unequivocally replicated and meta-analysis is not
supportive of such an association (Bertram et al., 2005).
Measures of total a-2M have not previously been reported to
differ between cases of Alzheimer’s disease and controls.
However, differences have been reported in Alzheimer’s
disease and controls between the different APOE genotypes
(Sacchi et al., 2002), perhaps because APOE and a-2M share,
and compete for, the same receptor. We can confirm this
finding as spot 4—containing only a-2M—correlates with
APOE genotype in the combined sample. We have validated
the 2-DGE/MS results for a-2M using semi-quantitative
western blotting. Interestingly, another proteinase inhibitor,
a1-antichymotrypsin, has also been suggested to be a blood-
based biomarker of Alzheimer’s disease in a study of similar
size (DeKosky et al., 2003).
However, the largest change we observed was in CFH
precursor. The >10-fold change initially observed was partly
due to floor-effects because of the relatively insensitive and
non-specific nature of 2-DGE—some individuals with
low amounts of CFH scored as having no CFH containing
spots on 2-DGE thus artificially increasing the difference
between cases and controls. However, using specific
immunoblots we were able to confirm that CFH shows a
significant increase in plasma in Alzheimer’s disease but not
in other neurodegenerative disorders. These data therefore
not only confirm that plasma markers differentiate between
Alzheimer’s disease and normal healthy controls but that
at least some of these changes are specific to this disease
and are not found in other neurodegenerative diseases.
Furthermore CFH is related to severity as levels inversely
correlate with cognitive decline. The increase in CFH with
decline is apparent even in the relatively early stages of
dementia as assessed using the Global Deterioration Scale
(GDS) (Reisberg et al., 1982) with an increase in CFH in
stages from GDS4 through GDS7. In stages 3 the subject is
deemed to be in a pre-dementia stage, stages 4 and 5 are
mild–moderate dementia where the patient has cognitive
impairment but relatively little impairment in basic activi-
ties of daily living. It is only in stage 7 that the patient is
severely affected and requires full nursing assistance.
CFH is a critical inhibitor of activation of the alternative
complement pathway [reviewed in Rodriguez et al. (2004)]
and has previously been shown to be present in plaques in
Alzheimer’s disease (Strohmeyer et al., 2002) although there
appears to be no increase in Alzheimer’s disease brain
(Strohmeyer et al., 2000) or CSF (Finehout et al., 2005).
There is a wide variation in normal plasma levels of CFH
(Esparza-Gordillo et al., 2004) and recently polymorphic
variation in the gene encoding CFH has been strongly
associated with age-related macular degeneration (AMD)
(Edwards et al., 2005; Hageman et al., 2005; Haines et al.,
2005). This is interesting as there is considerable overlap
between the pathologies of AMD and Alzheimer’s disease.
Like Alzheimer’s disease, AMD is characterized by Ab
deposition (Johnson et al., 2002) and associated with APOE
variation (Baird et al., 2004). In a longitudinal study
those with AMD were shown to be at increased risk for
Alzheimer’s disease (Klaver et al., 1999). In addition to Ab
and APOE, the drusen of AMD contain serum amyloid
p-component (Mullins et al., 2000), the precursor of which
was also found to be elevated in plasma in our study.
Ceruloplasmin, also previously implicated in both
Alzheimer’s disease and AMD (Newsome et al., 1986;
Loeffler et al., 1994), also showed differences between
Alzheimer’s disease and controls in our study.
Biomarker development requires at least three phases—
discovery, translation to a clinically utilizable form and
validation. Our study is firmly in the first of these categories.
None of the methods we have employed are feasible in
routine clinical practice and validation of diagnostic markers
requires very large, preferably prospective studies akin to
epidemiology whereas the study reported here, although
large for discovery is small for validation. Furthermore
we used immunoblot analysis for confirmation, an at best
semi-quantitative method. In order to validate either of
the proteins we have examined in this study as diagnostic
biomarkers it would be necessary to develop fully quan-
titative assays and test these in large, prospectively examined
populations. The test characteristics of any potential
biomarker are related to the assay and the sensitivity and
specificity we report here are unlikely to be the same for a
more quantitative assay. However, it was possible that
plasma based biomarkers would not be feasible in a brain
disease such as Alzheimer’s disease or that any changes in
plasma would be secondary to systemic illness and not
specific to a particular disease. Using a proteomic approach
we have shown that this null hypothesis is false, and have
discovered changes in Alzheimer’s disease, confirmed these
in a replication proteomic study and validated in a larger
data set using a complementary approach.
In summary, using a 2-DGE proteomics based approach
in Alzheimer’s disease plasma we find that the overall
pattern of protein spot distribution is both replicable and
moderately discriminative between Alzheimer’s disease cases,
normal controls and other neurodegenerative diseases. We
have identified 15 spots containing, in addition to albumin
and immunoglobulin fragments, a total of 11 proteins that
differ between cases and controls. The function of almost all
of these proteins is related to immune regulation adding
persuasively to the considerable body of evidence suggesting
an early inflammatory process in Alzheimer’s disease. Our
findings suggest furthermore that blood-based biomarkers
are a realistic objective in Alzheimer’s disease. The specificity
and sensitivity of both the 2-DGE and the immunoblot
assays of CFH and a-2M are below that required for a
biomarker but these are reproducible findings and suggest
that more quantitative assays based on the proteins we
report here may, independently or in combination, provide
a biomarker for diagnosis or to monitor disease progression.
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